Search

Your search keyword '"Charbonnier, Aude"' showing total 17 results
Start Over Author "Charbonnier, Aude" Publication Year Range Last 3 years
17 results on '"Charbonnier, Aude"'

1. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia

Author

Berton, Guillaume, Sedaki, Bochra, Collomb, Erwann, Benachour, Sami, Loschi, Michael, Mohty, Bilal, Saillard, Colombe, Hicheri, Yosr, Rouzaud, Camille, Maisano, Valerio, Villetard, Ferdinand, Corda, Evelyne D.'Incan, Charbonnier, Aude, Rey, Jerome, Hospital, Marie-Anne, Ittel, Antoine, Abbou, Norman, Fanciullino, Raphaelle, Dadone-Montaudié, Bérengère, Vey, Norbert, Venton, Geoffroy, Cluzeau, Thomas, Alary, Anne-Sophie, and Garciaz, Sylvain

Published
2024
Full Text
View/download PDF

4. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Author

Balsat, Marie, Alcazer, Vincent, Etienne, Gabriel, Huguet, Françoise, Berger, Marc, Cayssials, Emilie, Charbonnier, Aude, Escoffre-Barbe, Martine, Johnson-Ansah, Hyacinthe, Legros, Laurence, Roy, Lydia, Delmer, Alain, Ianotto, Jean-Christophe, Orvain, Corentin, Larosa, Fabrice, Meunier, Mathieu, Amé, Shanti, Andreoli, Annalisa, Cony-Makhoul, Pascale, Morisset, Stéphane, Tigaud, Isabelle, Rea, Delphine, and Nicolini, Franck Emmanuel

Published
2023
Full Text
View/download PDF

5. Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Author

Soua, Amel, Gilhodes, Julia, Iat, Alexandre, Hicheri, Yosr, Saillard, Colombe, Rouzaud, Camille, D'Incan, Evelyne, Rey, Jérôme, Mohty, Bilal, Charbonnier, Aude, Ittel, Antoine, Alary, Anne‐Sophie, Gelsi‐Boyer, Véronique, Murati, Anne, Lhoumeau, Anne‐Catherine, Devillier, Raynier, Boher, Jean‐Marie, Mozziconacci, Marie‐Joelle, Vey, Norbert, and Hospital, Marie‐Anne

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, OLDER patients, PLATELET count, OVERALL survival
Abstract

Introduction: Elderly acute myeloid leukemia (AML) patients with poor‐risk cytogenetics have a poor outcome with intensive chemotherapy (IC). While Venetoclax (VEN) has changed the outcomes of elderly unfit patients treatment, it is unknown whether it could be effective in poor‐risk cytogenetics 60–75 years old patients. Materials and Methods: We included 60–75‐year‐old AML patients eligible to allogenic stem cell transplantation (allo‐SCT) treated with VEN (combined with azacitidine or with Cladribin and Aracytine) at Institut Paoli Calmettes, between 2020 and 2023 and compared this cohort with patients treated by IC between 2010 and 2019. Results: Twenty six patients were treated with VEN (17 in combination with azacitidine and 9 with Cladribin and Aracytine) and 90 were treated with IC. Thirteen patients (50%) had a TP53 mutation. The median time for leucocyte and platelet counts recovery was 26 days (range 0–103) and 26 days (range, 0–63). The median duration of the first hospitalization was 32 days (ranges, 7–79). The composite response rate was 69% (CR = 50%, CRi = 4%, MLFS = 15%). Allo‐SCT could be performed in 42% of cases. Median overall survival (OS) was 7.9 months (20.9 months in the group of patients who transitioned to allo‐SCT). We found no difference with the historical cohort of patients treated with IC except a trend toward less lower and upper tract gastro‐intestinal (GI) tract infections in the VEN group (respectively 8% vs 26%, p =.06; and 0% vs. 13% p =.06). Conclusion: VEN‐based treatment was found to be effective in high risk AML can be considered as an alternative to IC in patients aged 60–75 with adverse cytogenetics. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience

Author

Blaise, Didier, Berger, Pierre, Mokart, Djamel, Camerlo, Jacques, Fougereau, Emmanuelle, Giovannini, Marc, Houvenaeghel, Gilles, Turrini, Olivier, Chabannon, Christian, Piana, Gilles, Brenot-Rossi, Isabelle, Tallet, Agnès, Gonçalves, Anthony, Charbonnier, Aude, Vey, Norbert, Grossi, Sabrina, and Viens, Patrice

Published
2021
Full Text
View/download PDF

7. Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques)

Author

Rea, Delphine, primary, Cayssials, Emilie, additional, Charbonnier, Aude, additional, Coiteux, Valérie, additional, Etienne, Gabriel, additional, Goldwirt, Lauriane, additional, Guerci-Bresler, Agnès, additional, Huguet, Françoise, additional, Legros, Laurence, additional, Roy, Lydia, additional, and Nicolini, Franck Emmanuel, additional

Published
2023
Full Text
View/download PDF

8. PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER.

Author

Berton, Guillaume, primary, Vicier, Cécile, additional, Hospital, Marie-Anne, additional, Saillard, Colombe, additional, Hicheri, Yosr, additional, Maisano, Valerio, additional, Villetard, Ferdinand, additional, Rouzaud, Camille, additional, Corda, Evelyne D’incan, additional, Rey, Jerome, additional, Mohty, Bilal, additional, Charbonnier, Aude, additional, Proux, Aurelien, additional, Vey, Norbert, additional, Goncalves, Anthony, additional, and Garciaz, Sylvain, additional

Published
2023
Full Text
View/download PDF

9. Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Author

Nicolini, Franck Emmanuel, primary, Dulucq, Stéphanie, primary, Boureau, Lisa, primary, Cony-Makhoul, Pascale, primary, Charbonnier, Aude, primary, Escoffre-Barbe, Martine, primary, Rigal-Huguet, Françoise, primary, Coiteux, Valérie, primary, Varet, Bruno, primary, Dubruille, Viviane, primary, Lenain, Pascal, primary, Rousselot, Philippe, primary, Rea, Delphine, primary, Guerci-Bresler, Agnès, primary, Legros, Laurence, primary, Liu, Jixing, primary, Gardembas, Martine, primary, Ianotto, Jean-Christophe, primary, Turlure, Pascal, primary, Johnson-Ansah, Hyacinthe, primary, Martiniuc, Juliana, primary, Jardel, Henry, primary, Joly, Bertrand, primary, Zunic, Patricia, primary, Henni, Tawfiq, primary, Villemagne, Bruno, primary, Berger, Marc G., primary, Cayssials, Emilie, primary, Guilhot, François, primary, Larosa, Fabrice, primary, Guilhot, Joëlle, primary, Etienne, Gabriel, primary, and Mahon, François-Xavier, primary

Published
2023
Full Text
View/download PDF

10. Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Author

Cortes, Jorge E., primary, Saikia, Tapan, additional, Kim, Dong-Wook, additional, Alvarado, Yesid, additional, Nicolini, Franck E., additional, Rathnam, Krishnakumar, additional, Khattry, Navin, additional, Punatar, Sachin, additional, Apperley, Jane F., additional, Charbonnier, Aude, additional, Deininger, Michael, additional, de Lavallade, Hugues, additional, Granacher, Nikki, additional, Gambacorti-Passerini, Carlo, additional, Lucchesi, Alessandro, additional, Mauro, Michael, additional, Vandenberghe, Peter, additional, Verhoef, Gregor, additional, Whiteley, Andrew R., additional, Nag, Arijit, additional, Apte, Shashikant, additional, Yao, Siu-Long, additional, Inamdar, Sandeep, additional, Dillu, Ruchika Irene, additional, Sreenivasan, Jayasree, additional, and Chimote, Geetanjali, additional

Published
2022
Full Text
View/download PDF

11. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Author

Dulucq, Stéphanie, primary, Nicolini, Franck E., additional, Rea, Delphine, additional, Cony-Makhoul, Pascale, additional, Charbonnier, Aude, additional, Escoffre-Barbe, Martine, additional, Coiteux, Valérie, additional, Lenain, Pascal, additional, Rigal-Huguet, Françoise, additional, Liu, Jixing, additional, Guerci-Bresler, Agnès, additional, Legros, Laurence, additional, Ianotto, Jean-Christophe, additional, Gardembas, Martine, additional, Turlure, Pascal, additional, Dubruille, Viviane, additional, Rousselot, Philippe, additional, Martiniuc, Juliana, additional, Jardel, Henry, additional, Johnson-Ansah, Hyacinthe, additional, Joly, Bertrand, additional, Henni, Tawfiq, additional, Cayssials, Emilie, additional, Zunic, Patricia, additional, Berger, Marc G., additional, Villemagne, Bruno, additional, Robbesyn, Fanny, additional, Morisset, Stephane, additional, Mahon, François-Xavier, additional, and Etienne, Gabriel, additional

Published
2022
Full Text
View/download PDF

12. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

Author

Garciaz, Sylvain, primary, Hospital, Marie-Anne, additional, Alary, Anne-Sophie, additional, Saillard, Colombe, additional, Hicheri, Yosr, additional, Mohty, Bilal, additional, Rey, Jérôme, additional, D’Incan, Evelyne, additional, Charbonnier, Aude, additional, Villetard, Ferdinand, additional, Maisano, Valerio, additional, Lombardi, Laura, additional, Ittel, Antoine, additional, Mozziconacci, Marie-Joelle, additional, Gelsi-Boyer, Véronique, additional, and Vey, Norbert, additional

Published
2022
Full Text
View/download PDF

13. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

Author

Plessier, Aurélie, primary, Esposito‐Farèse, Marina, additional, Baiges, Anna, additional, Shukla, Akash, additional, Garcia Pagan, Juan Carlos, additional, De Raucourt, Emmanuelle, additional, Ollivier‐Hourmand, Isabelle, additional, Cervoni, Jean‐Paul, additional, De Ledinghen, Victor, additional, Tazi, Zoubida, additional, Nousbaum, Jean‐Baptiste, additional, Bun, René, additional, Bureau, Christophe, additional, Silvain, Christine, additional, Tournilhac, Olivier, additional, Gerfaud‐Valentin, Mathieu, additional, Durand, François, additional, Goria, Odile, additional, Tellez, Luis, additional, Albillos, Agustin, additional, Gioia, Stefania, additional, Riggio, Oliviero, additional, De Gottardi, Andrea, additional, Payance, Audrey, additional, Rautou, Pierre‐Emmanuel, additional, Terriou, Louis, additional, Charbonnier, Aude, additional, Elkrief, Laure, additional, de la Tour, Regis Peffault, additional, Valla, Dominique‐Charles, additional, Gault, Nathalie, additional, and de Fontbrune, Flore Sicre, additional

Published
2022
Full Text
View/download PDF

14. Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study).

Author

Roy, Lydia, Chomel, Jean‐Claude, Guilhot, Joëlle, Guerci‐Bresler, Agnès, Escoffre‐Barbe, Martine, Giraudier, Stéphane, Charbonnier, Aude, Dubruille, Viviane, Huguet, Françoise, Johnson‐Ansah, Hyacinthe, Lenain, Pascal, Ame, Shanti, Etienne, Gabriel, Nicolini, Franck E., Rea, Delphine, Cony‐Makhoul, Pascale, Courby, Stéphane, Ianotto, Jean‐Christophe, Legros, Laurence, and Machet, Antoine

Subjects
CHRONIC myeloid leukemia, DASATINIB, CHRONIC leukemia, PROTEIN-tyrosine kinase inhibitors
Abstract

Summary: Superior rates of deep molecular response (DMR) have been reported with the combination of tyrosine kinase inhibitors and pegylated‐interferon‐alpha (Peg‐IFN) in patients with newly diagnosed chronic phase‐chronic myeloid leukaemia (CP‐CML). In this setting, this study investigated the efficacy and safety of dasatinib combined to Peg‐IFN‐α2b (Dasa‐PegIFN, NCT01872442). A total of 79 patients (age ≤65 years) started dasatinib; 61 were eligible for Peg‐IFNα‐2b add‐on therapy at month 3 for a maximum 21‐months duration. Dasatinib was continued thereafter. The primary endpoint was the cumulative rate of molecular response 4.5 log (MR4.5) by 12 months. The results are reported for the 5‐year duration of the study. Grade 3 neutropenia was frequent with the combination but did not induce severe infection (one of grade 3). Other adverse events were generally low grade (4% of grade 3–4) and expected. Seventy‐nine per cent and 61% of patients continued the Peg‐IFN until months 12 and 24, respectively. Overall, at these time points, MR4.5 rates were 25% and 38%, respectively. Thereafter, 32% and 46% of patients achieved a sustained (≥2 years) MR4.5 or MR4, respectively. This work established the feasibility and high rates of achievement of early and sustained DMR (a prerequisite for treatment‐free‐remission) with dasatinib and Peg‐IFNα‐2b combination as initial therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC

Author

Kaphan, Eléonore, Bettega, François, Forcade, Edouard, Labussière-Wallet, Hélène, Fegueux, Nathalie, Robin, Marie, Peffault De Latour, Régis, Huynh, Anne, Lapierre, Léopoldine, Berceanu, Ana, Marcais, Ambroise, Debureaux, Pierre-Edouard, Vanlangendonck, Nicolas, Bulabois, Claude-Eric, Magro, Leonardo, Daniel, Adrien, Galtier, Jean, Lioure, Bruno, Chevallier, Patrice, Antier, Chloé, Loschi, Michael, Guillerm, Gaelle, Mear, Jean-Baptiste, Chantepie, Sylvain, Cornillon, Jérome, Rey, Gaelle, Poire, Xavier, Bazarbachi, Ali, Rubio, Marie-Thérèse, Contentin, Nathalie, Orvain, Corentin, Dulery, Rémy, Bay, Jacques Olivier, Croizier, Carolyne, Beguin, Yves, Charbonnier, Aude, Skrzypczak, Caroline, Desmier, Déborah, Villate, Alban, Carré, Martin, and Thiebaut-Bertrand, Anne

Abstract

•Late relapse (>2 years) after allogeneic hematopoietic stem cell transplantation (AHSCT) for acute leukemia occurs at a frequency of 4.2%.•One-third of patients have extramedullary disease with persistent full donor chimerism.•Overall survival (OS) at 2 years after late relapse was 44%.•When feasible, OS is improved by a second AHSCT, without excess toxicity.

Published
2023
Full Text
View/download PDF

16. Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Author

Duranjou, Marine, Castoldi, Cécile, Alary, Anne Sophie, Hicheri, Yosr, Saillard, Colombe, Rouzaud, Camille, Charbonnier, Aude, Mohty, Bilal, D'Incan, Evelyne, Rey, Jerome, Hospital, Marie Anne, Devillier, Raynier, Vey, Norbert, Gelsi-Boyer, Véronique, Lhoumeau, Anne-Catherine, Murati, Anne, Golesi, Florence, Mozziconacci, Marie Joelle, Ittel, Antoine, and Garciaz, Sylvain

Published
2023
Full Text
View/download PDF

17. T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Author

Nicolini, Franck E., Charbonnier, Aude, Escoffre-Barbe, Martine, Jourdan, Eric, Roth-Guepin, Gabrielle, Berger, Marc G., Amé, Shanti, Simonet, Marion, Johnson-Ansah, Hyacinthe A., Dubruille, Viviane, Charbonnier, Amandine, Rousselot, Philippe, Orvain, Corentin, Joly, Bertrand, Ianotto, Jean-Christophe, Cayssials, Emilie, Meunier, Mathieu, Parry, Anne, Coiteux, Valerie, Legros, Laurence, Zerazhi, Hacene, Etienne, Gabriel, Quittet, Philippe, Legrand, Ollivier, Penot, Amelie, Roy, Lydia, Fouillet, Ludovic, Morisset, Stéphane, Tigaud, Isabelle, Mayet, Romaine, Garin, Gwenaëlle, Guitton, Jérôme, Dulucq, Stéphanie, and Huguet, Françoise

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results